Draegerwerk

Drägerwerk is a 5th-generation family-controlled German medical and safety equipment maker based in Lübeck, founded in 1889. The company splits into two roughly equal divisions: Medical (anesthesia workstations, ICU ventilators, neonatal incubators, patient monitoring) and Safety (industrial gas detection, fire-fighter SCBA respiratory protection, mine-safety, marine-safety equipment). The investment case for the preferred share (DRW3.DE) right now is a pure mean-reversion setup: the stock trades at 0.94x book value, 9.5x forward earnings, and a P/S of 0.43 — multiples not seen since the 2009 financial crisis bottom for a debt-light, family-owned, IP-rich industrial-medical compounder.

The depressed multiples reflect a real but transient problem: COVID-19 pulled forward roughly 18 months of ICU-ventilator demand into fiscal 2020-2021, and hospitals across Europe and North America have spent fiscal 2022-2025 working through inventory rather than ordering new equipment. Group operating margin compressed from 9.5 percent in fiscal 2020 to 2.5 percent in fiscal 2025 as fixed-cost absorption fell. Stefan Dräger has publicly guided to a return to mid-cycle margin of 6-7 percent by fiscal 2027, driven by an order-book normalization that began in late fiscal 2025. The chain of evidence so far supports the thesis: order intake grew 7 percent in Q1/2026 versus minus 4 percent in Q1/2025.

Drägerwerk has one of the most distinctive ownership structures in the DAX-mid universe. The Dräger family controls roughly 71 percent of the voting common stock through Drägerwerk Verwaltungs AG, and the preferred share (DRW3.DE) is the publicly tradeable instrument with no voting rights but priority dividend. Stefan Dräger (CEO since 2005, 5th-generation family member) and the family supervisory board members have made no public sales in the past decade — the family treats the company as multi-generational stewardship, not a quarterly-EPS optimization.

Among institutional preferred holders, Allianz Global Investors sits at approximately 4.2 percent and added in Q4/2025, DWS Top Dividende holds 3.1 percent, and Lazard Asset Management European Smaller Companies 2.4 percent. Three German sell-side analysts (Berenberg, Warburg, MM Warburg) upgraded to Buy in Q1/2026 with targets between 95 and 105 euros, and the consensus target of 97.25 euros implies roughly 20 percent upside. The recommendation column shows no Buy or Sell consensus (mostly Hold) — typical for a turnaround stock where conviction tracks the next quarter rather than long-term value.

At 81 euros DRW3.DE trades at 1.52 billion euros market cap, 0.43x trailing sales, 9.5x forward earnings, and 0.94x book value. Net debt is roughly 200 million euros against 124 million euros of trailing free cash flow — a 1.6x leverage ratio that is comfortable for an industrial-medical business. The standalone-sum-of-the-parts (Safety at 1.5 billion euros, Medical recovering to 0.8-1.0 billion euros, plus 200 million euros tangible book in excess net working capital) gives an asset-based fair value of 2.5-2.7 billion euros — a 60-75 percent uplift versus the current market cap. The mid-cycle EBITDA case (EBITDA of 320 million euros at 8x EV/EBITDA) supports 95-100 euros per preferred share, very close to the analyst consensus of 97.25 euros. Bear case (Medical fails to recover) keeps the stock at 65-70 euros — a roughly 15 percent drawdown protected by book value. The reward-to-risk skew is unusually favorable.

1. July 2026: H1/2026 results — first reporting period after the operating-leverage turn; consensus expects 4-5 percent organic revenue growth and EBIT margin expansion of 150-200 basis points
2. September 2026: Capital Markets Day — Stefan Dräger has been guiding to a mid-cycle margin target update at the event; a 7-percent-by-2027 reaffirmation would catalyze re-rating
3. Q4 2026: Multi-year hospital-ventilator replacement cycle inflection point — European and North American hospital operators have largely worked through 2020-2021 inventory and are due for the first major replacement wave by fiscal 2027

Drägerwerk preferred is one of the highest-conviction valuation-plus-quality setups I see in European mid-caps right now. The combination of below-book entry, family stewardship, unleveraged balance sheet, and a Safety division that alone covers the entire market cap is genuinely unusual. I size at 2 percent portfolio weight and add at any drawdown of 10-15 percent — and I have. The downside protection from tangible book value is real (Dräger trades real factories and inventory, not goodwill). The catalyst path is also clear: every quarter of order-book normalization compresses the time-to-recovery and re-rates the stock. The patience-required friction here is that mean reversion in German industrial medical names takes 24-36 months, not 6. If the H1/2026 numbers in July confirm the order-intake trend from Q1/2026, I would add to 2.5 percent weight. If Medical division margin disappoints, I would hold and re-evaluate at the September Capital Markets Day rather than panic-sell into a book-value floor.